Active, not recruitingPHASE1, PHASE2NCT06314490

Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

Studying Rare genetic disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Diego
Principal Investigator
Olivia Kim-McManus, M.D.
UCSD Rady Children's Hospital
Intervention
nL-SCN2A-002(drug)
Enrollment
1 enrolled
Eligibility
All sexes
Timeline
20242026

Study locations (1)

Collaborators

California Institute for Regenerative Medicine (CIRM) · n-Lorem Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06314490 on ClinicalTrials.gov

Other trials for Rare genetic disease

Additional recruiting or active studies for the same condition.

See all trials for Rare genetic disease

← Back to all trials